Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial

C Michael Gibson,Danielle Duffy,M Cecilia Bahit,Gerald Chi,Harvey White,Serge Korjian,John H Alexander,A Michael Lincoff,Mark Heise,Bronwyn A Kingwell,Jose C Nicolau,Renato D Lopes,Jan H Cornel,Basil S Lewis,Dragos Vinereanu,Shaun G Goodman,Christoph Bode,Ph Gabriel Steg,Peter Libby,Frank M Sacks,Kevin R Bainey,Paul M Ridker,Kenneth W Mahaffey,Philip Aylward,Stephen J Nicholls,Stuart J Pocock,Roxana Mehran,Robert A Harrington,AEGIS-II Committees and Investigators,Philip A Aylward,Deepak L Bhatt,John J P Kastelein,P Gabriel Steg,Michal Tendera,Pierluigi Tricoci,Cecilia Bahit,Gemma Figtree,Kurt Huber,Pascal Vranckx,Jose Carlos Nicolau,Nina Gotcheva,Kevin Bainey,Juan Carlos Prieto,Miguel Urina Triana,Miroslav Solar,Svend Eggert Jensen,Morten Bøttcher,Margus Viigimaa,Mika Laine,Gilles Montalescot,Tamaz Shaburishvili,Daniel Duerschmied,Dimitris Tousoulis,Michael Lee,Bela Merkely,Basil Lewis,Giuseppe Ambrosio,Satoshi Yasuda,Andrejs Erglis,Rimvydas Slapikas,Alan Fong,Jose Luis Leiva Pons,Vibeke Juliebø,Manuel Horna,Jaroslaw Trebacz,João Morais,Sergey Zenin,Nebojsa Tasic,Jack Tan,Jan Murin,Lesley Burgess,Hyun Jae Kang,Angel Cequier Fillat,Emil Hagström,Stephan Windecker,Jiunn-Lee Lin,Piyamitr Sritara,Umit Guray,Vijay Kunadian,Alexandr Parkhomenko,Marc Bonaca,Thomas J Povsic

DOI: https://doi.org/10.1093/eurheartj/ehae614

2024-09-02

Abstract:Background and aims: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given the well-established relationship between higher low-density lipoprotein cholesterol (LDL-C) and plaque burden, as well as greater risk reductions seen with PCSK9 inhibitors in patients with baseline LDL-C ≥100 mg/dL on statin therapy, the efficacy of CSL112 may be influenced by baseline LDL-C. Methods: Overall, 18,219 patients with acute MI, multivessel coronary artery disease, and additional risk factors were randomized to either four weekly infusions of 6 g CSL112 or placebo. This exploratory post-hoc analysis evaluated cardiovascular outcomes by baseline LDL-C in patients prescribed guideline-directed statin therapy at the time of randomization (n=15,731). Results: As baseline LDL-C increased, risk of the primary endpoint at 90 days lowered in those treated with CSL112 compared with placebo. In patients with LDL-C ≥100 mg/dL at randomization, there was a significant risk reduction of cardiovascular death, MI, or stroke in the CSL112 vs. placebo group at 90, 180, and 365 days (hazard ratio 0.69 [0.53-0.90], 0.71 [0.57-0.88], and 0.78 [0.65-0.93]). In contrast, there was no difference between treatment groups among those with LDL-C <100 mg/dL at baseline. Conclusions: In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥100 mg/dL. Further studies need to confirm that CSL112 efficacy is influenced by baseline LDL-C.